In Giessen - Marburg - Langen, DZIF researchers identify new active agents and vaccines and produce them in quality-assured production processes for scientific and industrial partners. Research activities are concentrated on developing strategies for combatting new or re-emerging infectious diseases in order to contain outbreaks of new pathogens, ofr example through quick, effective action and rapid vaccine development. Marburg focuses on viral pathogens, while Giessen concentrates on bacteria and antibiotic resistance. The institutions involved are combining into DZIF their infrastructures such as the BSL-4 high-security laboratory in Marburg and the BSL-3 laboratory at the Paul-Ehrlich-Institut in Langen. The Paul-Ehrlich-Institut (PEI) in Langen is contributing its expertise in drug approval and development to ensure the research results are swiftly put into practice.